The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.
Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should
AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r
Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo
California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, it
NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.